Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:16:23.056Z.
Calculation as of: 2026-10-06T16:16:23.056Z.
Quote observation: 2026-10-06T16:13:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4cebeea1a9b4d788b134268ad244658713bcf5e38577c227b803d15950d20ec6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.77M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.77M | N/A |
| enVVeno Medical Corporation (NVNO)vs › | $5.60M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.72M | N/A |
| Lucyd, Inc (LUCY)vs › | $5.85M | N/A |
| Scienture Holdings, Inc. (SCNX)vs › | $5.91M | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.98M | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.07M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.25M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
